Erythromelalgia
Erythromelalgia is a rare disease where neurogenic inflammation plays a role in the development of symptoms. The disease can cause near-constant or episodic pain (ranging from mild tingling to severe burning sensations), and redness to extremities.
The disease most commonly affects the feet but may also occur in the hands, face, or other parts of the body with both nerves and blood vessels involved. Symptoms are frequently managed through avoidance of pain triggers. The disorder can be extremely debilitating, with a significant negative impact on quality of life and with potential to impact mortality rates among young people and the suicide rates among adults.
PILA PHARMA aims to conduct a small proof of concept study in persons with erythromelalgia to demonstrate an effect of XEN-D0501 on reducing perceived pain during “flare ups”.
There are no current treatments available to patients. PILA PHARMA has made a draft clinical development plan for this project, and it is available for out-licensing.
In July 2022, the company received US Orphan Drug Designation for XEN-D0501 as treatment as the rare and painful disease erythromelalgia.
Erythromelalgia causes episodes of intense pain with swelling and redness of hands and feet.
Source: www.erythromelalgia.org
Founder / CSO / Chairman of Pila Pharma, Dorte X. Gram, interviews Matt Sondag about the thoughts and challenges of a living with erythromelalgia, a rare disease with periods of intense pain.
Please, find the link to the video (in English) here